EVE Health Group (ASX:EVE) has disclosed a binding exclusive Australian compounding agreement with Optimal Pharmacy Plus Stafford, signed on 10 November 2026, establishing a third commercial pathway for the company's patent-pending nano-emulsion pharmaceutical reformulation platform alongside its existing SAS-B and future full product registration channels.

Key Points

  • EVE signed a binding exclusive compounding agreement with Optimal Pharmacy Plus Stafford on 10 November 2026, with no upfront fees payable by EVE.
  • Under the agreement, EVE receives 75% and Optimal receives 25% of profit available for distribution after direct costs of compounding and delivery.
  • From first supply, Optimal is EVE's exclusive Australian compounder of the initial men's sexual health range and is restricted from compounding competing formulations.
  • EVE retains all intellectual property, product and formulation rights, including improvements made under the agreement.
  • First supply is subject to conditions including technology transfer and validation; no minimum volumes or guaranteed revenue apply, and EVE cannot yet estimate revenue.

Optimal Pharmacy Plus Stafford Compounding Agreement Terms

According to the company's filing, the agreement with Optimal Pharmacy Plus Stafford is binding and was signed on 10 November 2026. The arrangement is described as capital-light and partner-led, with EVE incurring no upfront fees. EVE will receive 75% of profit available for distribution after direct costs of compounding and delivery, with Optimal retaining 25%. Telehealth partners introduced by EVE will contract directly with Optimal for fulfilment. The filing states the agreement operates independently of the Libbo bioequivalence and registration program, representing a separate commercial channel.

Intellectual Property and Exclusivity Provisions

The filing states that EVE retains all intellectual property, product and formulation rights under the agreement, including any improvements made during the term. Optimal Pharmacy Plus Stafford is designated as EVE's exclusive Australian compounder of the initial men's sexual health range from the point of first supply and is restricted from compounding competing formulations. EVE's patent-pending nano-emulsion technology underpins the arrangement, with the filing confirming the science and IP remain with EVE throughout the agreement.

Libbo Product and Nano-Emulsion Platform

EVE's filing describes Libbo as a vardenafil oral dissolving film using nano-emulsion solubilisation to support transmucosal absorption. The company states onset of approximately 15 minutes is based on formulation design and an early 10-person observational study, with clinical validation to follow via a pilot pharmacokinetic study with dosing targeted for the fourth quarter of 2026 and a planned bioequivalence study. The filing describes the nano-emulsion platform as applicable to multiple high-value, poorly soluble compounds, with EVE noting preliminary partner discussions are underway across Asia, the Middle East, Europe and North America for post-registration rollout.